Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTA NASDAQ:HYFT NASDAQ:PRLD NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$11.33-0.2%$13.49$6.43▼$17.15$329.48M0.97188,790 shs447 shsHYFTMindWalk$1.81+9.0%$1.36$0.51▼$3.25$83.37M0.79440,083 shs82,602 shsPRLDPrelude Therapeutics$4.05+2.7%$4.26$0.75▼$5.54$307.49M1309,999 shs235,360 shsSOPHSOPHiA GENETICS$5.52+2.2%$4.97$2.59▼$5.70$373.34M0.9899,469 shs235,997 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+2.53%-5.65%-26.01%-19.90%+51.33%HYFTMindWalk+3.75%-15.74%+30.71%+29.69%+165,999,900.00%PRLDPrelude Therapeutics+2.60%+12.57%-18.93%+3.41%+233.90%SOPHSOPHiA GENETICS+2.27%+9.31%+4.85%+20.00%+88.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$11.33-0.2%$13.49$6.43▼$17.15$329.48M0.97188,790 shs447 shsHYFTMindWalk$1.81+9.0%$1.36$0.51▼$3.25$83.37M0.79440,083 shs82,602 shsPRLDPrelude Therapeutics$4.05+2.7%$4.26$0.75▼$5.54$307.49M1309,999 shs235,360 shsSOPHSOPHiA GENETICS$5.52+2.2%$4.97$2.59▼$5.70$373.34M0.9899,469 shs235,997 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+2.53%-5.65%-26.01%-19.90%+51.33%HYFTMindWalk+3.75%-15.74%+30.71%+29.69%+165,999,900.00%PRLDPrelude Therapeutics+2.60%+12.57%-18.93%+3.41%+233.90%SOPHSOPHiA GENETICS+2.27%+9.31%+4.85%+20.00%+88.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2979.04% UpsideHYFTMindWalk 2.60Moderate Buy$5.00176.24% UpsidePRLDPrelude Therapeutics 2.40Hold$7.6789.53% UpsideSOPHSOPHiA GENETICS 2.33Hold$7.5035.87% UpsideCurrent Analyst Ratings BreakdownLatest HYFT, SOPH, ENTA, and PRLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026HYFTMindWalk HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/6/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/4/2026PRLDPrelude Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/1/2026PRLDPrelude Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/28/2026PRLDPrelude Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/27/2026PRLDPrelude Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.004/21/2026SOPHSOPHiA GENETICS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ENTAEnanta Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026HYFTMindWalk JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.004/15/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.004/15/2026HYFTMindWalk JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$65.32M5.04N/AN/A$3.03 per share3.74HYFTMindWalk$17.59M4.75N/AN/A$0.37 per share4.89PRLDPrelude Therapeutics$12.14M26.54N/AN/A$1.09 per share3.71SOPHSOPHiA GENETICS$77.27M4.89N/AN/A$0.69 per share8.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)HYFTMindWalk-$21.69M-$0.20N/AN/AN/A-66.79%-69.37%-39.74%N/APRLDPrelude Therapeutics-$99.50M-$1.00N/AN/AN/AN/A-118.24%-66.12%8/13/2026 (Estimated)SOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%8/4/2026 (Estimated)Latest HYFT, SOPH, ENTA, and PRLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PRLDPrelude Therapeutics-$0.27-$0.13+$0.14-$0.13$4.58 million$4.58 million5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 million3/12/2026Q3 2026HYFTMindWalk-$0.04-$0.06-$0.02-$0.06$3.50 million$3.00 million3/10/2026Q4 2025PRLDPrelude Therapeutics-$0.33-$0.20+$0.13-$0.20$20.50 million$5.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AHYFTMindWalkN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A3.843.84HYFTMindWalk0.213.743.64PRLDPrelude TherapeuticsN/A2.032.03SOPHSOPHiA GENETICS1.052.061.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%HYFTMindWalk6.70%PRLDPrelude Therapeutics79.72%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals11.48%HYFTMindWalk6.83%PRLDPrelude Therapeutics49.20%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableHYFTMindWalk8046.16 million43.00 millionN/APRLDPrelude Therapeutics12079.64 million40.46 millionOptionableSOPHSOPHiA GENETICS52068.49 million65.14 millionNot OptionableHYFT, SOPH, ENTA, and PRLD HeadlinesRecent News About These CompaniesSOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting1 hour ago | prnewswire.comSophia Genetics, Memorial Sloan Kettering sign strategic collab for AI-powered precision oncology hubJune 9 at 3:38 AM | fiercehealthcare.comFInsider Spends US$99k Buying More Shares In SOPHiA GENETICSJune 7 at 2:52 PM | finance.yahoo.comSophia Genetics and MSK join forces to develop precision oncology hubJune 5, 2026 | yahoo.comSOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer CenterJune 4, 2026 | prnewswire.comSOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,750.00 in StockJune 1, 2026 | marketbeat.comSOPHiA GENETICS Files Form 6-K and Publishes 2025 ESG Impact SummaryMay 19, 2026 | tipranks.comSynnovis and SOPHiA GENETICS partner to bring blood-based cancer testing to patients across UKMay 15, 2026 | pharmabiz.comPSynnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.May 13, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), SOPHiA GENETICS (SOPH) and Solventum Corporation (SOLV)May 9, 2026 | theglobeandmail.comSOPHiA Genetics (SOPH) Q1 2026 Earnings TranscriptMay 5, 2026 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comBTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8May 5, 2026 | finance.yahoo.comSOPHiA GENETICS Reports First Quarter 2026 ResultsMay 5, 2026 | prnewswire.comUncovering MTAP deletions in precision oncology researchApril 30, 2026 | labroots.comLHow The SOPHiA GENETICS (NasdaqGS:SOPH) Narrative Is Shifting With New Fair Value TargetsApril 26, 2026 | finance.yahoo.comSOPHiA GENETICS SAApril 23, 2026 | edition.cnn.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026April 21, 2026 | prnewswire.comMount Sinai adopts AI platform to advance genomic testingApril 18, 2026 | beckershospitalreview.comBSOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken Sells 2,800 SharesApril 17, 2026 | insidertrades.comMount Sinai uses AI to enhance the speed of genomic testingApril 16, 2026 | healthcareitnews.comHNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameBy Leo Miller | June 1, 2026The Pentagon's AI Pivot Supercharges Defense StocksBy Jeffrey Neal Johnson | May 19, 20263 Dividend Kings That Earn Their Crown Every QuarterBy Chris Markoch | May 31, 2026HYFT, SOPH, ENTA, and PRLD Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$11.33 -0.02 (-0.18%) As of 09:44 AM Eastern This is a fair market value price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.MindWalk NASDAQ:HYFT$1.81 +0.15 (+9.04%) As of 09:45 AM Eastern This is a fair market value price provided by Massive. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.Prelude Therapeutics NASDAQ:PRLD$4.04 +0.11 (+2.66%) As of 09:45 AM Eastern This is a fair market value price provided by Massive. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.SOPHiA GENETICS NASDAQ:SOPH$5.52 +0.12 (+2.22%) As of 09:44 AM Eastern This is a fair market value price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass Optical Cable Corporation: Strong Earnings, But Hurdles Remain The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
